PERI’s comprehensive three-day oncology course reviews current and emerging drugs, immunotherapies, their application to specific cancer types, how to conduct clinical trials for oncologic therapies, and the drug development process for drug candidates leading to their approval. The US Food & and Drug Administration (FDA) regulatory considerations for Oncology drugs, registration endpoints, and accelerated and breakthrough approval mechanisms are also covered. This course is ideal for individuals transitioning into the oncology field to explore a variety of cancer types, as well as fundamental components of developing therapies for cancer, including nonclinical development, toxicology, dosing, clinical trial design, and regulatory considerations. New this fall: post-marketing drug safety and medical affairs!
- Provider:Pharmaceutical Education & Research Institute
- Activity Link: https://peri.org/open-courses/cancer-october-2024/
- Start Date: 2025-10-23 05:00:00
- End Date: 2025-10-23 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 12.25 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all